Q2 2021 Xvivo Perfusion AB Earnings Call Transcript
Ladies and gentlemen, welcome to the XVIVO Group Interim Report Q2 2021. I will now hand over to Dag Andersson, CEO. Sir, please begin.
()-&
Yes. good morning, good afternoon and good evening anywhere in the world you are right now and welcome to the second quarterly telephone conference 2021. I am happy to present with my CEO -- CFO, Kristoffer Nordstrom.
And as mentioned in the quarterly report, which was released this morning, we had a strong second quarter from many aspects. Sales, margins and EBITDA showed very positive performance. Sales in local currencies increased by 116% in the quarter. Gross margin of nondurable goods, 76% and EBITDA margin adjusted of 14%. These are very strong numbers. And on top of that, an organic growth of 82% for the thoracic business area also worth mentioning since this is actually an exceptionally strong number.
The level of recovery within organ transplantation varies from country to country. In the U.S
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |